NO. 2926

FORM PTO-1595 1-31-92 (modified)

RECORDATION FORM COVER SHEET **PATENTS ONLY**

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

| | I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, Washington, D.C. 20231, Patent and Trademark Assignment System, at (703) 306-5995, on Date |
|---|--|
| To the Commissioner of Data to Bu | Signature Janese James |
| Name of conveying party(ies): | d the attached original documents or copy thereof. |
| Aventis Pharma S.A | Name and address of receiving party(ies): |
| Additional name(s) of conveying party(ies) attached? YES NO | Name: Aventis Pharmaceuticals Products Inc. Internal Address: 500 Arcola Road City: Collegeville State: PA 718: 10426 |
| 3. Nature of Conveyance: Assignment | Additional name(s) and address(es) attached? |
| Execution Date: February 28, 2000 | |
| Name: Paul R. Darkes Internal Address: Aventis Pharmaceuticals Inc. Street Address: Route 202-206 / P.O. Box 6800 City: Bridgewater State: NJ ZIP: 08807-0800 | B. Patent No.(s): ed? YES NO 6. Total number of applications and patents involved: 1 7. Total (37 CFR 3.41): \$40.00 Enclosed Authorized to be charged to deposit account |
| Our Reference No.: A1729C US | B. Deposit account number: 18-1982 |
| | |
| DO NOT USE THIS SPACE Statement and signature. | |
| To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document. | |
| aul R. Darkes, Reg. No. 33,862 Name of Person Signing | - face Afrey be |
| MB No. 0651-0011 (exp. 4/94) | Date: Signature Total number of pages comprising cover sheet: 2 |

Do not detach this portion

Mail documents to be recorded with required cover sheet information to:

Commissioner for Patents Box Assignments Washington, D.C. 20231

Washington, D.C. 20231

Public burden reporting for this sample cover sheet is estimated to average about 30 minutes per document to be recorded, including time for reviewing the document and gathering the data needed, and completing and reviewing the sample cover sheet. Send comments regarding this burden estimate to the U.S. Patent and Trademark Office, Office Information Systems, PK2-1000C, Washington, D.C. 20231, and to the Office of Management and Burdet. Panamork Reduction Project (0581-0011). Weighlanden and to the Office of Management and Budget, Paperwork Reduction Project (0561-0011), Washington,

PATENT

REEL: 012419 FRAME: 0567

File No. A1729C-US

ASSIGNMENT AND AGREEMENT

PROCESS FOR PREPARING N6-SUBSTITUTED ADENOSINE DERIVATIVES

and all the rights and privileges, including any and all benefits under the International Convention for the Protection of Industrial Property, including the right to claim priority based on said United States application, and under any and all Letters Patent which may be granted therefor, and all right, title and interest in and to every patent application filed or to be filed on said invention in any other country or patent organization, including continuations, divisions, renewals, revivals, and any substitute applications of said United States application, and any and all patents which may issue thereon, and any reissues, pipelines and extensions, and governmental exclusivity rights of the same.

I/we authorize and request competent authorities to grant and issue any and all patents on said invention to said assignee or its successor, assigns and legal representatives, or to such nominees as said assignee may designate.

I/we agree that, when requested, I/we will, without charge to said assignee but at its expense, sign all papers, take all rightful oaths, and do all acts which may be necessary, desirable or convenient for securing and maintaining patents for said invention in any and all countries and for vesting title thereto in said assignee, its successors, assigns, legal representatives or nominees.

I/we covenant with said assignee, its successors, assigns and legal representatives, that the rights and property herein conveyed are free and clear of any encumbrance, and that I/we have full right to convey the same as herein expressed.

AVENTIS PHARMAS.A

(Printed Name of Person Signing)

Title: Sentin

PATENT
RECORDED: 02/22/2002 REEL: 012419 FRAME: 0568